AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

Vadadustat clinical data on display for nephrologists and healthcare providers

CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it will present data at the  on June 4-7, 2025, both virtually and live in Vienna.

Akebia-supported presentations at ERA Congress 2025:



  • Free Communication 15: Novel CKD Treatments Beyond the Pillars

    Abstract No. 3359

    Dr. Glenn Chertow to present on Friday, June 6 at 8:15 am CEST


  • E-Poster No. 2908


  • E-Poster No. 1325



About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at , which does not form a part of this release.

Akebia Therapeutics Contact

Mercedes Carrasco



EN
27/05/2025

Underlying

AKBAAkebia Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Akebia Therapeutics Inc.

 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics to Present at the Leerink Partners 2026 Global Hea...

Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in a Fireside Chat at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9 at 8:00 AM ET. A webcast of the presentation can be accessed through the “Investors” section o...

March 3, 2026 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rul...

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly-hired employees options to purchase an aggregate of 46,200 shares of Akebia’s common stock on February 27, 2026. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exer...

March 2, 2026 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financia...

Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo® (vadadustat) revenue growth in 2026 through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates Pipeline advancement continues with enrollment underway for praliciguat Phase 2 clinical trial in focal segmental glomerulosclero...

February 26, 2026 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financ...

Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights Akebia to Host Conference Call on February 26 at 8:00 a.m. EST CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, February 26, 2026, prior to the open of financial markets. Akebia will host a conference call on Thursday, February 26, 2026, at 8:00 a.m. EST to discuss its financial results and recent business highlights. T...

February 19, 2026 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Bio...

Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that members of its executive team will participate in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12 at 9:30 AM EST. A webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at following the conference. The Emerging Outlook: ...

February 4, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch